AEON Biopharma Inc Ordinary Shares - Class A AEON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.28
- Day Range
- $0.25–0.28
- 52-Week Range
- $0.18–1.45
- Bid/Ask
- $0.25 / $0.26
- Shares Outstanding
- 49.88M
- Market Cap
- $13.47M
- Volume/Avg
- 2M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 8
- Website
- https://www.aeonbiopharma.com
Valuation
|
Metric
|
AEON
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AEON
Financial Strength
|
Metric
|
AEON
|
|---|---|
Quick Ratio | 0.47 |
Current Ratio | 0.54 |
Interest Coverage | — |
Quick Ratio
AEON
Profitability
|
Metric
|
AEON
|
|---|---|
Return on Assets (Normalized) | −174.57% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AEON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|J>$#!h | LOCK|@<&Xk | $128B | |||
| Moderna Inc
MRNA
| LOCK|MT!N^@# | LOCK|&H | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Xnf!fs | LOCK|FV$p | $75B | |||
| argenx SE ADR
ARGX
| LOCK|trQgnk | LOCK|V> | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&MpTKBG | LOCK|Lx% | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d!Y?CN | LOCK|J^Q># | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?&>PrgpM | LOCK|gyhN# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#$Skt# | LOCK|!C | $25B | |||
| Incyte Corp
INCY
| LOCK|#?dw^% | LOCK|%k? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|crP<S!P | LOCK|?<# | $15B |
United States